- $183.77m
- $58.47m
- $72.76m
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025
Brief: Compugen Reports Fourth Quarter and Full Year 2024 Results
Brief: Compugen Announces FDA Clearance Of IND For COM503 For Treatment Of Solid Tumors
Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial
Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial
Brief: Compugen To Receive Milestone Payment Triggered By Dosing Of First Patient In The Second Phase 3 Trial Evaluating Rilvegostomig
Brief: Compugen Ltd Solid Balance Sheet With Extended Cash Runway Expected To Fund Operations Into 2027
Brief: Compugen Appoints David Silberman As Chief Financial Officer
Brief: Compugen To Receive $10 Mln Milestone Payment
Brief: Compugen Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. STOCKS ON THE MOVE-Enphase, Boeing, Kenvue
Compugen surges on licensing deal with Gilead for cancer therapy
Brief: Compugen Says Co Will be Eligible to Receive $10 Mln Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial
Brief: Gilead, Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Brief: Compugen As Of Sept. 30, 2023, Cash, Cash Equivalents And Cash Investments Were About $57.5 Million
Brief: Compugen's COM701 (Anti-PVRIG) Mediates Anti-Tumor Activity In Patients Typically Not Responding To Immunotherapy